Wearing-off Identification in Parkinson's Disease: The shapd-woq Study

被引:7
|
作者
Wan, Ying [1 ]
Yuan, Canxing [2 ]
Hou, Xiaojun [3 ]
Chen, Wei [4 ]
Wang, ChunYan [5 ]
Gao, Shan [6 ]
Wang, Yuhui [7 ]
Jin, Lingjing [8 ]
Liu, Zhenguo [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Neurol, Shanghai, Peoples R China
[3] Second Mil Med Univ, Affiliated Changhai Hosp, Dept Neurol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Dept Neurol, Shanghai Peoples Hosp 9, Sch Med, Shanghai, Peoples R China
[5] Shanghai Yangpu Hosp Tradit Chinese Med, Dept Neurol, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Dept Neurol, Affiliated People Hosp 6, Shanghai, Peoples R China
[7] Shanghai Punan Hosp, Dept Neurol, Shanghai, Peoples R China
[8] Tongji Univ, Sch Med, Tongji Hosp, Dept Neurol, Shanghai, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2020年 / 11卷
基金
国家重点研发计划; 美国国家科学基金会;
关键词
Parkinson's disease; wearing-off phenomenon; patient self-assessments; pre-visiting screening; validity; QUESTIONNAIRE; MOTOR;
D O I
10.3389/fneur.2020.00116
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To clarify the frequency of wearing-off phenomenon (WO) and the validity of the Chinese version of the 9-item wearing-off questionnaire (CWOQ-9) in WO identification in this large population. Methods: Parkinson's patients treated with antiparkinsonian medications were consecutively recruited into this observational, cross-sectional investigation. Patients completed the CWOQ-9 prior to the independent clinician assessment. Results: A total of 1,385 patients were included in the analysis. The mean age was 69.7 +/- 9.5 years and the mean disease duration was 5.8 +/- 4.7 years. Clinicians identified WO in 763 patients, with an overall prevalence of 55.1%. In patients within 1 year of disease duration, clinicians diagnosed WO in eight patients, with a percentage of 12.9%. With the disease progression, the WO frequency gradually increased to 76.2% in patients with 10-15 years of disease duration. Then, it slowly decreased at a longer disease duration. The occurrence of WO was closely associated with the disease duration, H&Y staging, and levodopa daily dose. CWOQ-9 identified 1,071 patients (1071/1398, 77.33%) that had WO-related symptoms. The mean CWOQ-9 score was 3.4 +/- 1.6. CWOQ-9 corresponded with clinician assessments of WO in 734 of 763 cases; clinicians disagreed with the CWOQ-9 considering the presence of WO in 337 of 1,071 cases. The sensitivity and specificity of CWOQ-9 were 96.2 and 45.8%, respectively. Conclusions: WO occurred frequently at the early and middle stage of PD. CWOQ-9 was qualified as a pre-visiting screening tool for clinicians to better identify WO.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Wearing-off in Parkinson's disease: neuropsychological differences between on and off periods
    Caillava-Santos, Fabiane
    Margis, Regina
    de Mello Rieder, Carlos Roberto
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1175 - 1180
  • [12] Frequency of Wearing-Off Symptoms in Parkinson's disease Fluctuators: An on/off evaluation
    Perepezko, K.
    Hinkle, J.
    Mills, K.
    Pontone, G.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S344 - S344
  • [13] Role of the pharmacist in the effective management of wearing-off in Parkinson's disease
    Simonson, William
    Hauser, Robert A.
    Schapira, Anthony H. V.
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (11) : 1842 - 1849
  • [14] Correlation Between Lacunae and the Wearing-off Phenomenon in Parkinson's Disease
    Zhang, Meimei
    Chen, Huimin
    Liu, Genliang
    Wang, Xuemei
    Wang, Zhan
    Feng, Tao
    Zhang, Yumei
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 67 - 74
  • [15] The efficacy of istradefylline for treating mild wearing-off in Parkinson's disease
    Kitagawa, M.
    Yabe, I.
    Takahashi, I.
    Matushima, M.
    Sasaki, H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 364 - 365
  • [16] Risk factors of wearing-off phenomenon in Parkinson's disease in Japan
    Fukae, J.
    Ouma, S.
    Kashihara, K. -I.
    Hattori, N.
    Tsuboi, Y.
    [J]. MOVEMENT DISORDERS, 2016, 31 : S495 - S496
  • [17] Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study
    Rinaldi, Domiziana
    Assogna, Francesca
    Sforza, Michela
    Tagliente, Stefania
    Pontieri, Francesco E.
    [J]. NEUROLOGICAL SCIENCES, 2018, 39 (01) : 141 - 143
  • [18] Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study
    Domiziana Rinaldi
    Francesca Assogna
    Michela Sforza
    Stefania Tagliente
    Francesco E. Pontieri
    [J]. Neurological Sciences, 2018, 39 : 141 - 143
  • [19] Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia
    Alessandra Fanciulli
    Francesca Assogna
    Carlo Caltagirone
    Gianfranco Spalletta
    Francesco E. Pontieri
    [J]. Aging Clinical and Experimental Research, 2013, 25 : 601 - 603
  • [20] The QUICK questionnaire identifies wearing-off in Parkinson's disease patients
    Martinez-Martin, P.
    Tolosa, E.
    Hernandez, B.
    Badia, X.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S221 - S221